Substance, composition, or device? EPO addresses method of reaching a decision

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Substance, composition, or device? EPO addresses method of reaching a decision

Sponsored by

inspicos-400px recrop.jpg
Patent Health Care Pharmaceuticals Innovation concept. Copy rights patented certified medicine.

While concrete definitions are still lacking, Peter Koefoed of Inspicos says patent applicants seeking protection for second medical uses of products could now find it easier to build their case

Under Article 53(c) of the European Patent Convention (EPC), methods of therapy or surgery for humans and animals are exempted from patentability, as are diagnostic methods carried out on the human or animal body. At the same time, Article 53(c) specifies that this exemption does not apply to products – in particular, substances and compositions – for use in these methods.

Moreover, Article 54(5), by legal fiction, acknowledges novelty of any "substance or composition" for use in such exempted methods that are themselves novel. It can be derived from the wording of the latter provisions that they only apply to a subset of the products mentioned in Article53(c): substances and compositions.

Board of appeal case law has previously sought to establish criteria for determining whether a product is a substance or composition and not a device. These criteria are laid down in the Guidelines for Examination, G-VI, 6.1.1, which states that a product qualifies as a substance or composition if it is the active agent or ingredient in the specific medical use and if the therapeutic effect can be ascribed to its chemical properties (see G 5/83 and T 1758/15).

In decision T 1252/20 (relating to peptides used in cancer treatment by mechanically blocking blood vessels), of February 6 2024, the board saw no basis in the EPC for considering the mode of action of the claimed substance or composition to determine compliance with Article 54(5). The board pointed out that the exempted methods in Article 53(c) are not merely medical methods but also surgery and diagnostic methods. Moreover, the precise mode of action of a product is not always known. The board hence concluded that it is only relevant to consider whether the claimed product is a substance or composition but not to consider its mode of action.

T 1252/20 does not offer a concrete definition of a substance or composition. Nevertheless, applicants may face fewer obstacles when seeking protection at the EPO for second medical uses of products in cases where the claimed product at face value does not have device-like features.

more from across site and SHARED ros bottom lb

More from across our site

In the wake of controversy surrounding Banksy’s recent London mural, AJ Park’s Thomas Huthwaite and Eloise Calder delve into the challenges street artists face in protecting their works and rights
Alex Levkin, founder of iPNOTE, discusses reshaping the filing industry through legal tech, and why practitioners’ advice should stretch beyond immediate legal needs
Cohausz & Florack, together with Krieger Mes & Graf von der Groeben, have taken action against Amazon on behalf of three VIA LA licensors
In the fourth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss unconscious bias in the IP workplace and how to address it
Greg Munt, who has moved from Griffith Hack to James & Wells after four decades, hails his new firm’s approach to client service
Practitioners warn that closing the Denver regional office could trigger a domino effect, threatening local innovation and access to IP resources
Law firms are rethinking litigation strategies after USPTO director John Squires said he would take control of PTAB challenges
News of Singapore planning to streamline the licensing framework for foreign law firms and a partnership between Avanci and Xprize were also among the top talking points
In major recent developments, the court also ruled on another request concerning access to documents and appointed a new panel to the Court of Appeal
A new foundation in Chile is giving women in the IP community the mentorship, and visibility they’ve long lacked
Gift this article